RegenHU

What RegenHU does

RegenHU is a privately held Swiss Med Tech company founded in 2007 and headquartered in Villaz-St-Pierre, Switzerland. The company designs and manufactures 3D bioprinting instruments — primarily the R-GEN 100 and R-GEN 200 systems — paired with its proprietary SHAPER software for designing 2D and 3D constructs and managing biofabrication workflows. Its core technology integrates multiple printing modalities (cell suspensions, thermoplastics, and biomaterials) within a single robotic platform, enabling applications in human skin printing, cellular drug discovery models, and personalized tablet formulation.

The company serves a diversified customer base spanning academic research institutions (ETH Zurich, TU Berlin, University of Minnesota, Trinity College, University of Michigan, UMC Utrecht), pharmaceutical R&D (Novartis), and cosmetics (L'Oreal). A database of 732 scientific publications referencing RegenHU technology demonstrates established adoption across the global research community. Customer support is delivered through a scientific advisory team, technical engineering hotline, and the RegenHU Bioprinting Academy for training.

RegenHU generates revenue primarily through capital equipment sales (R-GEN bioprinters), supplemented by software licenses (SHAPER) and professional services (training and support). The company operates a consultative, sales-led GTM motion with quote-based pricing and direct engagement. Cumulative disclosed funding since inception totals approximately $700K across multiple small rounds led by NIVALIS Group and Venture Kick, with no rounds reported after 2015, indicating a bootstrapped or organically financed operating model.

Name

RegenHU

Legal name

regenHU

Website

https://regenhu.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

RegenHU is a Swiss Med Tech company that designs and manufactures 3D bioprinting instruments (R-GEN 100 and R-GEN 200) and SHAPER software for academic researchers, pharmaceutical companies, and cosmetics firms developing tissue models, drug discovery assays, and personalized therapeutics.

Ownership category

akta.pro rank

Product category

3D Bioprinting Instruments and Biofabrication Equipment

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG)

akta.pro secondary industry

3D Bioprinting & Biofabrication (HLAAAGAC)

Keywords

• 3D bioprinters
• Bioprinting software
• Tissue engineering
• Biofabrication platforms
• Drug discovery models

Headquarters

HQ city

Villaz-saint-pierre

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. 3D Bioprinting Instruments: Sale of bioprinting hardware including R-GEN 100 and R-GEN 200 systems for tissue models, drug development, and tablet formulation
2. Software Licenses: SHAPER software for bioprinting design and process management
3. Support and Training Services: RegenHU Bioprinting Academy training, technical engineering support via hotline, and scientific advisory services for instrument selection and protocol development

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

RegenHU develops, manufactures, and sells 3D bioprinting instruments and software used by research and pharmaceutical organizations to fabricate tissue models, drug discovery cellular models, and personalized pharmaceutical tablets. Its product platform comprises the R-GEN 100 and R-GEN 200 bioprinters paired with SHAPER software, integrating cell suspension, thermoplastic, and biomaterial printing technologies under a single robotic control system.

Product overview

RegenHU offers a unified bioprinting platform consisting of the R-Gen 100 and R-Gen 200 3D bioprinters combined with SHAPER software. The platform combines multiple printing technologies (from cell suspensions to thermoplastic and biomaterial printing) in a single 3D bioprinting process. Applications include human skin printing for wound healing and cosmetic research, tablet printing for personalized medicine with high API loading, and cellular drug discovery models for target validation and disease modeling.

Differentiator

Problem solved

Functional benefit

Brands

• R-GEN 100: 3D bioprinter model for tissue models, drug development and tablet formulation
• R-GEN 200
• SHAPER

Products and services

• R-GEN 100 A 3D bioprinter designed for tissue models, drug development, and tablet formulation, combining multiple printing technologies (cell suspensions, thermoplastics, and biomaterials) in a single bioprinting process for academic and pharmaceutical researchers.
• R-GEN 200 An advanced 3D bioprinter for biofabrication applications including human skin printing, cellular drug discovery models, and personalized medicine, featuring precise robotic control and multi-technology printing capabilities for research and pharmaceutical users.
• SHAPER Bioprinting software that enables users to design 2D and 3D constructs, define materials and labware, manage the entire bioprinting project, specify calibration, dispensing parameters, and non-dispensing actions, and monitor processes in real time for biofabrication workflows.

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/regenhu

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds8 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RegenHU